123639-56-5

Basic information

• Product Name: N-BENZYL-L-SERINE, METHYL ESTER
• Synonyms: N-BENZYL-L-SERINE, METHYL ESTER;Methyl (S)-2-(Benzylamino)-3-hydroxypropanoate;L-N-Benzylserine Methyl Ester;N-(phenylMethyl)-L-serine Methyl Ester;(S)-Methyl 2-(benzylaMino)-3-hydroxypropanoate
• CAS NO: 123639-56-5
• Molecular Formula: C₁₁H₁₅NO₃
• Molecular Weight: 209.24
• Product Categories: Amino Acids 13C, 2H, 15N;Amino Acids & Derivatives
• Mol File: 123639-56-5.mol
• Article Data: 36

Chemical Properties

• Boiling Point: 351.127°C at 760 mmHg
• Flash Point: 166.156°C
• Appearance: /
• Density: 1.15g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.534
• Storage Temp.: Refrigerator
• Solubility: Acetone, Chloroform, Ethanol, Ethyl Acetate, Methanol
• PKA: 13.94±0.10(Predicted)
• CAS DataBase Reference: N-BENZYL-L-SERINE, METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: N-BENZYL-L-SERINE, METHYL ESTER(123639-56-5)
• EPA Substance Registry System: N-BENZYL-L-SERINE, METHYL ESTER(123639-56-5)

Safety Data

• Hazardous Substances Data: 123639-56-5(Hazardous Substances Data)

Usage

Chemical Properties

White Waxy Solid

InChI:InChI=1/C11H15NO3/c1-15-11(14)10(8-13)12-7-9-5-3-2-4-6-9/h2-6,10,12-13H,7-8H2,1H3/t10-/m0/s1

Upstream product

• 40216-75-9 N-benzylidene-L-serine methyl ester 
• 5680-80-8 methyl (2S)-2-amino-3-hydroxypropanoate hydrochloride 
• 100-52-7 benzaldehyde 
• 100-39-0 benzyl bromide 
• 2788-84-3 (S)-serine methyl ester 
• 67-56-1 methanol 
• 106910-76-3 (S)-2-(benzylamino)-3-hydroxypropanoic acid 
• 40216-75-9 (R)-3-Hydroxy-2-{[1-phenyl-meth-(E)-ylidene]-amino}-propionic acid methyl ester 
• 5874-57-7 R-(-)-serine methyl ester hydrochloride 
• 2104-89-4 D-serine methyl ester 

Downstream Products

• 145236-97-1 methyl (2S,4S)-2-thiomethyl-2-oxo-3-benzyl-1,3,2-oxazaphospholidine-4-carboxylate 
• 145307-20-6 methyl (2R,4S)-2-thiomethyl-2-oxo-3-benzyl-1,3,2-oxazaphospholidine-4-carboxylate 
• 158012-71-6 methyl N-benzyl-N-(tert-butoxycarbonyl)-L-serinate 
• 123621-73-8 Methyl (2S,4S)-2-Chloro-2-oxo-(syn)-3-benzyl-1,3,2-oxazaphospholidine-4-carboxylate 
• 123672-99-1 Methyl (2R,4S)-2-Chloro-2-oxo-3-benzyl-1,3,2-oxazaphospholidine-4-carboxylate 
• 158012-74-9 N-benzyl-N-benzyloxycarbonyl-L-serine methyl ester 
• 131110-77-5 (S)-3-Benzyl-2,2-dimethyl-oxazolidine-4-carboxylic acid methyl ester 
• 184532-44-3 methyl (S)-2-benzylamino-3-(tert-butyldimethylsilyloxy)propionate 
• 123621-73-8 (S)-3-Benzyl-2-chloro-2-oxo-2λ⁵-[1,3,2]oxazaphospholidine-4-carboxylic acid methyl ester 
• 123621-76-1 Methyl (2S,4S)-2-Phenoxy-2-oxo-3-benzyl-1,3,2-oxazaphospholidine-4-carboxylate 
• 123673-02-9 Methyl (2R,4S)-2-Phenoxy-2-oxo-3-benzyl-1,3,2-oxazaphospholidine-4-carboxylate 
• 145451-89-4 (2R,4S)-3-Benzyl-2-tert-butyl-oxazolidine-4-carboxylic acid methyl ester 
• 866392-20-3 N-benzyl-N-methyl-L-serine methyl ester 
• 1001054-44-9 (3S)-methyl 4-benzyl-6-(iodomethyl)-6-methylmorpholine-3-carboxylate 

Relevant articles and documents

Structure-based design and pharmacokinetic optimization of covalent allosteric inhibitors of the mutant gtpase krasg12c

Attempts to directly drug the important oncogene KRAS have met with limited success despite numerous efforts across industry and academia. The KRASG12C mutant represents an "Achilles heel" and has recently yielded to covalent targeting with small molecules that bind the mutant cysteine and create an allosteric pocket on GDP-bound RAS, locking it in an inactive state. A weak inhibitor at this site was optimized through conformational locking of a piperazine-quinazoline motif and linker modification. Subsequent introduction of a key methyl group to the piperazine resulted in enhancements in potency, permeability, clearance, and reactivity, leading to identification of a potent KRASG12C inhibitor with high selectivity and excellent cross-species pharmacokinetic parameters and in vivo efficacy.

TETRACYCLIC HETEROARYL COMPOUNDS

The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

Amino-acid ester bromide type chiral ionic liquid and preparation method thereof

The invention provides an amino-acid ester bromide type chiral ionic liquid and a preparation method thereof. The structural formual of the amino-acid ester bromide type chiral ionic liquid is as shown in the specification. In the structural formula, R is